Date:3/20/2012

eveloper of highly selective ion channel drugs for the treatment of atrial fibrillation.  Utilising its world-leading expertise in the discovery of potent and selective drugs, Xention is focusing on the potassium channels Kv1.5 and IKACh which are widely recognised by cardiologists as the preferred targets for the prevention of atrial fibrillation.  Xention's lead drug candidate XEN-D0103, a Kv1.5 antagonist, is at the end of phase 1 clinical development and has demonstrated a very high degree of selectivity over non-atrial ion channels.  The company has also developed antagonists of IKACh which are highly potent and selective, and an IKACh development candidate will be selected shortly.

Xention has signed two major research collaborations with Ono Pharmaceutical Co Ltd and the Grϋnenthal Group, which take advantage of its strong experience in ion channel discovery and which are focused on the development of clinical candidates in other therapeutic areas.

Xention is based in Cambridge, UK and employs over 50 people. For further information, please visit http://www.xention.com.

For further information, please contact:

Tim Brears, CEO, Xention Limited, +44(0)1223-493-900

Amber Bielecka / Claire Dickinson, M:Communications, xention@mcomgroup.com, +44(0)20-7920-2352

'/>"/>

SOURCE Xention Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
2. EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
3. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
4. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
5. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
6. Gen-Probe Reports Financial Results for the Fourth Quarter of 2011
7. Neuland Labs Reports Third Quarter Fiscal Year 2012 Financial Results
8. Cepheid Reports Fourth Quarter and Full Year 2011 Results
9. Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M
10. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
11. Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184